From MarketBeat:

Moody Aldrich Partners LLC invested in shares of Neurocrine Biosciences. The institutional investor bought 4,863 shares worth $547,000. Several other hedge funds and institutional investors also added or reduced their stakes in NBIX. Insiders have sold shares of company stock valued at $35,043,864 in the last 90 days. Neurocrine Biosciences stock opened at $141.74 on Friday and currently has a consensus rating of “Moderate Buy” with a consensus target price of $134.69. Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders.

In further news, insider Darin Lippoldt sold 10,919 shares of Neurocrine Biosciences stock for a total transaction of $1,225,876.13. Insider Jude Onyia sold 2,331 shares of Neurocrine Biosciences stock for a total transaction of $264,731.67. Neurocrine Biosciences stock opened at $141.74 on Friday and currently has a consensus rating of “Moderate Buy” with a consensus target price of $134.69.

Neurocrine Biosciences last released its quarterly earnings results on Tuesday, October 31st, with a net margin of 10.71% and a return on equity of 10.54%. The company had revenue of $498.80 million during the quarter, compared to analyst estimates of $479.09 million. Sell-side analysts predict that Neurocrine Biosciences, Inc. will post 2.17 EPS for the current year.

Overall, Neurocrine Biosciences, Inc. has a 1 year low of $89.04 and a 1 year high of $143.35. The stock has a market capitalization of $13.93 billion, a P/E ratio of 76.20, a P/E/G ratio of 0.76 and a beta of 0.25. Insiders have sold a total of 270,631 shares of company stock valued at $35,043,864 in the last 90 days. 4.40% of the stock is owned by insiders. Six equities research analysts have rated the stock with a hold rating and nineteen have assigned a buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $134.69.



Read more: Moody Aldrich Partners LLC Purchases New Shares in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)